Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study.
Rifat Emral,Cem Haymana,Ibrahim Demirci,Ilker Tasci,Mustafa Sahin,Erman Cakal,Naim Ata,Ugur Unluturk,Tevfik Demir,Derun Taner Ertugrul,Ibrahim Sahin,Aysegul Atmaca,Osman Celik,Murat Caglayan,Kazim Yalcin Arga,Selcuk Dagdelen,Serpil Salman,Ilhan Satman,Alper Sonmez +18 more
TLDR
In this paper, the effect of preexisting treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) on COVID-19-related hospitalization and mortality in patients with type 2 diabetes mellitus (T2DM) was investigated.Abstract:
To investigate the effect of preexisting treatment with dipeptidyl peptidase-4 inhibitors (DPP-4is) on COVID-19-related hospitalization and mortality in patients with type 2 diabetes mellitus (T2DM). A multicenter, retrospective cohort study was conducted using patient data extracted from the Turkish National Electronic Database. All patients who tested positive for COVID-19 (PCR test) between 11 March through to 30 May 2020 were screened for eligibility (n = 149,671). Following exclusion of patients based on pre-determined inclusion criteria, patients with T2DM using a DPP-4i or glucose-lowering medications other than a DPP-4i were compared for mortality and hospitalization. The propensity score method was used to match age, gender, micro- and macrovascular complications, and medications in the two groups. Independent associates of mortality were analyzed using multivariable analysis on the whole T2DM population. A total of 33,478 patients with T2DM who tested postive for COVID-19 who met the inclusion criteria were included in the analysis. Median (interquartile range) age was 54 (22) years and 42.4% were male. Of these, 9100 patients using DPP-4is (n = 4550) or other glucose-lowering drugs (n = 4550) were matched in two groups. After matching, analysis revealed a lower mortality in the DPP-4i group (9.5 vs. 11.8%; p < 0.001). In the multivariable model, the use of DPP-4is (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.35–0.91; p = 0.02) was associated with lower mortality in the whole sample, while age, male gender, computed tomography finding of COVID-19, obesity, low glomerular filtration rate, and an insulin-based regimen also predicted increased risk of death. There was no association between the preexisting treatment with DPP-4is and COVID-19-related hospitalization in the matched analysis or multivariate model. The rate of admission to the intensive care unit and/or mechanical ventilation favored the DPP-4i group (21.7 vs. 25.2%; p = 0.001), although this association became saturated in the multivariate analysis (OR 0.65, 95% CI 0.39–1.08; p = 0.099). The results of this study demonstrate an association between DDP-4i use and reduced mortality in people with T2DM who tested PCR positive for COVID-19.read more
Citations
More filters
Journal ArticleDOI
Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis
N. Nguyen,D. S. Ho,H. Nguyen,Dang Khanh Ngan Ho,Hung-Yuan Li,Chia-Yuan Lin,H.-Y. Chiu,Yang Ching Chen +7 more
TL;DR: In this paper , the effects of pre-admission use of antidiabetic medications on the in-hospital mortality of patients with COVID-19 having type 2 diabetes were compared.
Journal ArticleDOI
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients
Ákos Nádasdi,György Sinkovits,Ilona Bobek,B. Lakatos,Zsolt Förhécz,Zita Z. Prohászka,Marienn Réti,Miklós Arató,Gellért Cseh,Tamás Masszi,Béla Merkely,Péter Ferdinandy,Istvan Valyi-Nagy,Zoltán Prohászka,Gábor Firneisz +14 more
TL;DR: Investigation of serum circulating DPP4 activity in patients with COVID-19 disease found a significant decrease was found in study groups of higher disease severity and is a strong prognostic biomarker of mortality.
Journal ArticleDOI
Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients?
Rumeysa Selvinaz Erol,Esra Şen,Feyza Yener Ozturk,Zeynep Sarac,Gizem Leyla Kokoglu,Muhammed Masum Canat,Duygu Yildiz,Yunus Emre Aytekin,Dilek Yildiz Sevgi,Yuksel Altuntas +9 more
TL;DR: It is demonstrated that the use of DPP-4i by patients with T2DM in catching COVID-19 does not affect the mortality due to CO VID-19, the severity of COVID -19 disease, and 3-month post-discharge mortality.
Journal ArticleDOI
Noninsulin‐based antihyperglycemic medications in patients with diabetes and COVID‐19: A systematic review and meta‐analysis
Mahmoud Nassar,Hazem Maarouf Abosheaishaa,Awadhesh Kumar Singh,Anoop Misra,Zachary T. Bloomgarden +4 more
TL;DR: In this paper , the authors evaluated different noninsulin AGMs in patients with COVID-19 infection and found that patients with diabetes are more likely to suffer COVID•19 complications.
Journal ArticleDOI
The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review
TL;DR: In this article , the authors present a narrative review of the literature in order to set light into the relationship between COVID-19 infection and DM/hyperglycemia, and the risk may be higher for those without pre-existing DM.
References
More filters
Journal ArticleDOI
Is DPP4 inhibition a comrade or adversary in COVID-19 infection.
Rinkoo Dalan,Rinkoo Dalan +1 more
TL;DR: This commentary presents a nuanced debate on why the DPP4i may not bebeneficial in COVID-19 and that caution needs to be addressed in making any judgements until real world data is available.
Journal ArticleDOI
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
Jianghua Zhou,Bin Wu,Wenxin Wang,Fang Lei,Xu Cheng,Juan-Juan Qin,Jingjing Cai,Xiao-Jing Zhang,Feng Zhou,Ye-Mao Liu,Haomiao Li,Lihua Zhu,Zhi-Gang She,Xin Zhang,Juan Yang,Hongliang Li +15 more
TL;DR: It is demonstrated that DPP4i use is not significantly associated with poor outcomes of COVID-19 or other adverse effects of anti-diabetic treatment, and the data support the continuation of DPP 4i agents for diabetes management in the setting of CO VID-19.
Journal ArticleDOI
Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: A nationwide study (TurCoviDia).
Alper Sonmez,Ibrahim Demirci,Cem Haymana,Ilker Tasci,Selcuk Dagdelen,Serpil Salman,Naim Ata,Ibrahim Sahin,Rifat Emral,Erman Cakal,Aysegul Atmaca,Mustafa Sahin,Osman Celik,Tevfik Demir,Derun Taner Ertugrul,Ugur Unluturk,Murat Caglayan,Ilhan Satman +17 more
TL;DR: In this paper, a nationwide retrospective cohort of patients with Type 2 Diabetes mellitus (T2DM) hospitalized with confirmed COVID-19 infection from 11 March to 30 May 2020 in the Turkish Ministry of Health database was investigated.
Journal ArticleDOI
Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul.
Ilhan Satman,Ibrahim Demirci,Cem Haymana,Ilker Tasci,Serpil Salman,Naim Ata,Selcuk Dagdelen,Ibrahim Sahin,Rifat Emral,Erman Cakal,Aysegul Atmaca,Mustafa Sahin,Osman Celik,Tevfik Demir,Derun Taner Ertugrul,Ugur Unluturk,Kazim Yalcin Arga,Murat Caglayan,Alper Sonmez +18 more
TL;DR: In this article, the clinical outcomes of patients with and without Type 2 diabetes mellitus (T2DM) during the first hit of COVID-19 in Istanbul were compared.
Journal ArticleDOI
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19.
TL;DR: In this paper, Sous presse et al. propose corriges corrigues par l'auteur. Disponible en ligne depuis le jeudi 7 janvier 2021